<DOC>
	<DOCNO>NCT00434031</DOCNO>
	<brief_summary>The purpose study evaluate rate pathologic complete response give docetaxel trastuzumab follow caelyx ( liposomal doxorubicin ) , cyclophosphamide trastuzumab surgery treat woman operable locally advanced HER-2 positive breast cancer .</brief_summary>
	<brief_title>CETRA : Neoadjuvant Caelyx Trastuzumab Her-2 Positive Breast Cancer</brief_title>
	<detailed_description>Chemotherapy association trastuzumab , monoclonal antibody , give surgery , show reduce tumor size permit good resection HER-2 positive breast cancer . This study evaluate activity neoadjuvant treatment docetaxel trastuzumab give every 3 week 4 cycle , follow combination caelyx , cyclophosphamide trastuzumab every 3 week 4 cycle . Patients undergo breast cancer surgery 2-5 week completion neoadjuvant therapy . Adjuvant therapy surgery give accord exist guideline , include additional 10 cycle trastuzumab .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<criteria>Histological diagnosis breast cancer Stage IIIIIB ( T01234N+M0 T234N0M0 ; accord TNM AJCC classification , 2002 ) Hyperexpression HER2/neu ( HercepTest 3+ positive FISH test ) Age &gt; 18 e &lt; 65 year Left ventricular ejection fraction ( LVEF ) &gt; = 55 % ECOG Performance Status 02 Neutrophils &gt; = 2000/mm続 , platelet &gt; = 100.000/mm続 , hemoglobin &gt; = 10 g/dl ) , GOT , GPT bilirubin &lt; 1.25 x upper normal limit , creatinine &lt; 1.25 x upper normal limit . Life expectancy &gt; 3 month Signed informed consent . Any prior treatment breast cancer Metastatic disease ( M1 ) Performance status ( ECOG ) &gt; = 3 Current malignancy history prior malignancy within past 10 year ( exception adequately treat nonmelanoma skin cancer carcinoma situ uterine cervix ) Neutrophils &lt; 2.000/mm続 , platelet &lt; 100.000/mm続 , hemoglobin &lt; 10 g/dl . Creatinine &gt; 1.25 x upper normal limit GOT and/or GPT and/or bilirubin &gt; 1.25 x upper normal limit . Concomitant condition , investigator 's opinion , contraindicate use drug protocol . Congestive heart failure history congestive heart failure , unstable angina pectoris , myocardial infarction , clinically significant valvulopathy uncontrolled arrhythmias Active infection Incapacity refusal provide inform consent . Inability comply follow Pregnant nursing female .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>July 2012</verification_date>
	<keyword>locally advanced</keyword>
	<keyword>stage II</keyword>
	<keyword>stage IIIa</keyword>
	<keyword>stage IIIb</keyword>
	<keyword>HER-2 positive</keyword>
	<keyword>primary</keyword>
</DOC>